Among patients with CBF‐AML, the incidence of PTR (33.3% vs 28.9%, P = 1.000, Figure 1C) and the posttransfusion PI (P = .847, Figure 1D) was comparable in patients with or without c‐Kit mutations. This evidence concerns the gene CEBPZ and acute myeloid leukemia.